MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinsonism"

  • MDS Virtual Congress 2020

    Developing A Novel Disease-Specific Psychosis Severity Scale in Parkinson’s disease (Psy-PD): A Pilot Study

    Y.M Wan, E.K Tan, D. Aarsland, T.S Lee, Y.L Lo, SKS. Ting, P. Martinez-Martin, K.R Chaudhuri (London, United Kingdom)

    Objective: To develop and assess the psychometrics of a disease-specific psychosis severity rating scale (Psy-PD) for a one-stop assessment of change in psychotic symptoms in…
  • MDS Virtual Congress 2020

    The short- and long-term outcomes of STN DBS in PD patients with or without RBD

    S.M Park, R. Kim, J.H Shin, H.J Kim, B.S Jeon (Seoul, Republic of Korea)

    Objective: We aimed to assess the short- and long-term outcomes of bilateral subthalamic (STN) deep brain stimulation (DBS) including the motor performance and quality of…
  • MDS Virtual Congress 2020

    Technology-based therapy response and prognostic biomarkers in Parkinson’s disease: results from a prospective evaluation of a de novo PD patients’ cohort

    G. Di Lazzaro, M. Ricci, T. Schirinzi, S. Scalise, G. Saggio, N.B Mercuri, A. Pisani (Rome, Italy)

    Objective: To prospectively evaluate motor performances with technology-based objective measures (TOMs) in a cohort of PD patients in order to identify therapy response and prognostic…
  • MDS Virtual Congress 2020

    PD Conversations: Creation of an Online Parkinson’s Community

    N. Yarab, D. Ojeda, J. McClure, A. Janicke, V. Todaro, L. Pearl, C. Whitlock, A. Diaz (Miami, FL, USA)

    Objective: An online Parkinson’s community can provide a valuable forum and an effective means of support for individuals living with Parkinson’s disease (PD). Background: Parkinson’s…
  • 2019 International Congress

    Long-term impact of Levodopa Carbidopa Intestinal Gel (LCIG) on reducing “Off” time: Results from a systematic review of studies with ≥ 12 months of follow-up

    A. Antonini, P. Odin, R. Pahwa, J. Aldred, A. Alobaidi, Y. Jalundhwala, P. Kukreja, L. Bergmann, S. Inguva, Y. Bao, K. Chaudhuri (North Chicago, IL, USA)

    Objective: The objective of this study was to summarize evidence evaluating long-term (i.e. ≥ 12 months)efficacy of levodopa carbidopa intestinal gel (LCIG) on “off” time,…
  • 2019 International Congress

    Changes to Speech Production after SpeechVive Treatment in Individuals with Parkinson’s Disease

    J. Huber, E. Stathopoulos, J. Sussman, K. Richardson, D. Matheron, S. Snyder (West Lafayette, IN, USA)

    Objective: The purpose of the present study was to assess the effects of a device-driven treatment (SpeechVive) on respiratory and laryngeal function after 8 weeks…
  • 2019 International Congress

    Continuous circadian intracerebroventricular administration of anaerobic dopamine: A new therapeutic concept for Parkinson’s disease?

    C. Moreau, C. Laloux, C. Lachaud, E. Pioli, Q. Li, P. Pascal, L. Defebvre, R. Bordet, E. Bezard, M. Fisichella, D. Devos (Lille, France)

    Objective: We aim to overcome these challenges by demonstrating that continuous i.c.v. of Anaerobic-dopamine (A-dopamine,Patent #WO2015173258 A1) close to the striatum is a feasible and…
  • 2019 International Congress

    Yerba mate tea (Ilex paraguariensis) exerts a neuroprotective effect on intrastriatal 6-OHDA-lesioned mice model of Parkinson’s disease

    I. Taravini, G. Gomez, L. Tribbia, A. Cura, R. Rivero, M. Bernardi, J. Ferrario, B. Baldi-Coronel, O. Gershanik, E. Gatto (Gualeguaychú, Argentina)

    Objective: We set to investigate the possible neuroprotective effect of yerba mate (YM) consumption on dopaminergic neurons in a mice model of Parkinson’s disease (PD). Background: The motor…
  • 2019 International Congress

    Progression of neuropsychiatric symptoms in Parkinson’s disease

    J. Dlay, G. Duncan, T. Khoo, C. Williams-Gray, D. Breen, R. Barker, D. Burn, R. Lawson, A. Yarnall (Newcastle Upon Tyne, United Kingdom)

    Objective: To determine the progression of neuropsychiatric symptoms (NPS) in Parkinson’s disease (PD) and their associations with quality of life (QoL) and motor problems. Background:…
  • 2019 International Congress

    Comparison of Gene Expression in Parkinson’s Disease and Bipolar Disorder

    FV. Delos Reyes (Quezon City, Philippines)

    Objective: The aim of this research is to compare the overexpressed genes in patients with Parkinson's Disease (PD) and patients with Bipolar Disorder (BD) versus…
  • « Previous Page
  • 1
  • …
  • 128
  • 129
  • 130
  • 131
  • 132
  • …
  • 405
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #24970 (not found)
  • Comorbid Normal Pressure Hydrocephalus with Parkinson’s disease: a call for clinical awareness
  • Common mistakes in the MoCA test in patients with Parkinson’s Disease in Kyrgyzstan
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley